Subscribe
shutterstock_1653845269_taljat_david
Taljat David / Shutterstock.com
4 January 2022AmericasMuireann Bolger

Novartis upholds MS drug patent at Fed Circ

Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya (fingolimod hydrochloride) was valid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Boston Pharma reaches deals with GSK and Novartis
4 October 2018   Boston Pharmaceuticals yesterday signed deals with GSK and Novartis, licensing eight drug candidates in total.
Big Pharma
Fed Circuit reverses Novartis’ drug patent win
23 June 2022   The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.
Biotechnology
Biotech wins $16.5 million in drug royalties dispute
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Boston Pharma reaches deals with GSK and Novartis
4 October 2018   Boston Pharmaceuticals yesterday signed deals with GSK and Novartis, licensing eight drug candidates in total.
Big Pharma
Fed Circuit reverses Novartis’ drug patent win
23 June 2022   The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.
Biotechnology
Biotech wins $16.5 million in drug royalties dispute
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

More on this story

Americas
Boston Pharma reaches deals with GSK and Novartis
4 October 2018   Boston Pharmaceuticals yesterday signed deals with GSK and Novartis, licensing eight drug candidates in total.
Big Pharma
Fed Circuit reverses Novartis’ drug patent win
23 June 2022   The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.
Biotechnology
Biotech wins $16.5 million in drug royalties dispute
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility